Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Table 3 Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and all-cause mortality (n=83)

Model	MMP-1			MMP-2			MMP-3			MMP-9			MMP-10			TIMP-1
Model	HR	95% CI	p va ue	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
1	1.62	1.28; 2.06	<0.001	1.93	1.48; 2.51	<0.001	1.82	1.38; 2.41	<0.001	1.39	1.14; 1.69	0.001	1.33	1.06; 1.67	0.015	2.10	1.55; 2.85	<0.001
2	1.38	1.07; 1.78	0.012	1.60	1.19; 2.15	0.002	1.39	1.05; 1.85	0.021	1.18	0.95; 1.46	0.133	1.13	0.90; 1.41	0.313	1.39	0.97; 1.98	0.070
3	1.45	1.10; 1.92	0.008	1.50	1.07; 2.09	0.017	1.32	0.95; 1.83	0.100	1.17	0.93; 1.46	0.179	1.01	0.78; 1.30	0.943	1.15	0.75; 1.74	0.529
4	1.34	1.04; 1.73	0.026	1.57	1.17; 2.10	0.002	1.40	1.06; 1.86	0.019	1.12	0.90; 1.40	0.314	1.12	0.90; 1.41	0.316	1.29	0.89; 1.87	0.173
5	1.47	1.13; 1.92	0.004	1.58	1.17; 2.12	0.002	1.41	1.07; 1.87	0.015	1.18	0.95; 1.45	0.132	1.13	0.90; 1.41	0.307	1.33	0.93; 1.92	0.118

HR hazard ratio for all-cause mortality per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
Model 3 Model 2 + eGFR and Ln-UAE
Model 4 Model 2 + inflammatory z-score
Model 5 Model 2 + endothelial dysfunction z-score

ISSN: 1475-2840